Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
Abingdon Life Sciences, Inc. is a Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model.
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
CARLSBAD, Calif., July 21 /PRNewswire/ -- Abingdon Life Sciences
announces the formal opening of its offices in Carlsbad, California. The
offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad
Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences,
Inc. is a first-in-class Drug, Device, Diagnostic Development Management
Organization (DDMO), focused on providing drug and device companies with
superior services based on an integrated strategic development model. An
integrated development model focuses on the Target Product Profile (TPP)
concept, and allows a platform to be assessed by key areas of opportunity
and risk from both scientific and business aspects.
Abingdon was founded on the principle that a proactive strategic
approach to development will yield better outcomes. Abingdon's philosophy
is to provide clients with a focused approach to product development by
building synergistic partnerships that use significant expertise to achieve
the best outcome. Global core-competencies include pre-clinical, regulatory
strategy and submissions, clinical development, biostatistics, report
writing and post-marketing obligations. Abingdon provides services to
clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA,
PMA and 510k applications. Abingdon's senior executives provide
personalized oversight and leadership of projects to ensure the best
possible customer experience. Key alliances enable Abingdon to assist with
cGMP services from formulation development for clinical trial supply
through commercialization.
"Abingdon's approach is to reduce the noise in the development process
and provide objective direction that outlines the risks and benefits of the
potential development pathways. In the end, our goal is to assist our
clients to streamline their development process and help make decisions
that will achieve their goals. We believe this will ultimately reduce costs
to our clients and speed the time to market," stated Aidan Nuttall, Ph.D.,
President and C.O.O., Abingdon Life Sciences, Inc.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device
Development Management Organization (DDMO) providing drug and device
companies superior clinical and regulatory services based on an integrated
strategic development model. Abingdon's senior executives provide
personalized oversight and leadership of projects to ensure the best
possible customer experience.
SOURCE Abingdon Life Sciences, Inc.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
